- About: India ranks 3rd globally in pharmaceutical production by volume and 14th largest in terms of value, supplying over 50% of global vaccine demand and 40% of generic medicines in the US.
- Size: The Indian pharmaceutical industry for FY 2023-24 is valued at USD 50 billion, contributing around 1.72% to the GDP, and is projected to reach USD 130 billion by 2030.
- India’s biotechnology sector, valued at USD 137 billion in 2022, aims for USD 300 billion by 2030.
- Key Segments:
- Generic Medicines: India is the world’s largest supplier, meeting 20% of global demand.
- Active Pharmaceutical Ingredients (APIs): India produces over 500 APIs, contributing 8% to the global API market.
- Medical Devices: The market is projected to grow from USD 11 billion to USD 50 billion by 2030.
- Growth Drivers:
- Affordable Pricing: Indian drugs are significantly cheaper than Western alternatives.
- Government Support: Policies such as the Production-Linked Incentive (PLI) scheme promote domestic manufacturing.
- Strong R&D Base: India has a large pool of scientists and engineers driving innovation e.g., India now ranks 6th globally in terms of patent applications, with 64,480 patent filings in 2023.
- Increasing Global Demand: Rising chronic diseases and an aging global population fuel demand for cost-effective medicines.
- Exports: India exports medicines to over 200 nations, with FY24 exports reaching USD 27.82 billion.
- India ranks 12th globally in medical goods exports, driven by rising demand for biosimilars and specialty drugs.
- Government Initiatives: Production Linked Incentive Scheme (PLI), Promotion of Bulk Drug Parks Scheme, National Medical Device Policy 2023.
Note: APIs are the biologically active components in a drug that produce the intended therapeutic effect. They are the key ingredients responsible for treating or managing a medical condition.
Challenges the Pharma Industry Face
- Quality Issues: Concerns over the quality of Indian medicines have emerged due to incidents like the Gambia cough syrup deaths in 2022.
- Regulatory Hurdles: Compliance with evolving Good Manufacturing Practice (GMP) and quality control regulations is costly.
- Dependence on API Imports: India imports 70% of APIs, primarily from China, creating supply chain vulnerabilities.
- Pricing Pressures: Strict price controls under National List of Essential Medicines (NLEM), impact the profitability of pharma companies hindering innovation incentives for Industry.
- Global Competition: There is rising competition from China, the US, and the EU (highly sophisticated and well researched products), while Vietnam and Indonesia emerge as manufacturing hubs.
- Skill Shortage: There is a lack of trained professionals in biotechnology, biosimlars and drug discovery.
- E.g., dependence on generic drugs rather than innovative formulations affects global competitiveness.
Way Forward
- Domestic API Manufacturing: PLI 2.0, bulk drug parks, fermentation-based APIs, and green chemistry can strengthen API production, ensuring self-reliance and supply stability.
- Expanding High-Value Drug Markets: Indian firms should expand R&D in gene therapies, personalized medicine, and mRNA and next-gen vaccines to tap into growing specialty therapy opportunities.
- Enhancing R&D: R&D incentives through tax benefits, research grants, and public-private partnerships (PPPs), AI-driven drug discovery, big data in clinical
- trials, and telemedicine will boost innovation and patient outcomes.
- Regulatory & Quality Compliance: Faster approvals for biosimilars, innovative drugs, and breakthrough therapies will improve time-to-market.
- Enhancing drug safety monitoring will boost consumer trust and regulatory credibility.
- Global Market Penetration: Expanding exports to Africa, Latin America, and ASEAN via trade deals and overseas manufacturing will overcome trade barriers and boost growth.
-
Sale Product on saleUPSC CSE 2026 Online Course
₹64,500.00Original price was: ₹64,500.00.₹54,500.00Current price is: ₹54,500.00.Rated 5.00 out of 5 based on 2 customer ratings -
Sale Product on saleUPSC CSE 2027 Online Course
₹79,500.00Original price was: ₹79,500.00.₹69,500.00Current price is: ₹69,500.00.Rated 5.00 out of 5 based on 3 customer ratings -
Sale Product on saleUPSC CSE 2028 Online Course
₹94,500.00Original price was: ₹94,500.00.₹84,500.00Current price is: ₹84,500.00.Rated 5.00 out of 5 based on 3 customer ratings